Sakata Pharmaceutical Haikou to Roll Out Kubota Glasses Business in China Recently, Sakata Pharmaceutical, a Japanese company, signed a cooperation agreement with Kubota Pharmaceutical Holdings, a Tokyo Stock Exchange-listed firm. According to the agreement, Kubota Pharmaceutical has designated Sakata Pharmaceutical (Hainan) Co., Ltd., a wholly-owned subsidiary of Sakata Pharmaceutical, as the sole entity for establishing the Kubota Glass business in China. Additionally, the two parties have initiated a joint research and development mechanism to achieve localized production of core components in Hainan by 2025.
Unlike traditional glasses that only passively correct vision, Kubota Glass myopia prevention and control glasses create dynamic defocus signals around the retina through precision optical design. This activates a biological feedback mechanism for eye axis regulation, applying new myopia prevention and control technology to daily wear.
Sakata Pharmaceutical primarily engages in China-Japan medical and health industry project cooperation. In September 2024, officials from Haikou International Investment Promotion Bureau visited Sakata Pharmaceutical in Japan to introduce free trade port policies and Haikou’s biopharmaceutical industry. In November 2024, the Sakata Pharmaceutical project was signed at the Haikou Industry Investment Conference, and registered Sakata Pharmaceutical (Hainan) Co., Ltd. as a foreign-funded wholly-owned subsidiary in Haikou National Hi-Tech Industrial Development Zone. In February 2025, Sakata Pharmaceutical signed an agreement with Himawari Medical Corporation to jointly conduct regenerative medical project cooperation in China, relying on the “pioneering and experimental” policy advantages of the Hainan Free Trade Port to establish a fast track for international advanced medical technology transformation.
Source: Hainan Daily, Securities Herald
Sakata Pharmaceutical Haikou to Roll Out Kubota Glasses Business in China Recently